OXB Signs AAV Manufacturing Deal with Plowshare Therapies

OXB, a global cell and gene therapy CDMO, has signed an agreement with Plowshare Therapies, a biotechnology company developing gene therapies for rare genetic diseases, under which OXB will provide process development and AAV GMP manufacturing services to Plowshare, with the potential to support additional programs and later-stage manufacturing as Plowshare’s pipeline advances.

The partnership is rooted in a shared commitment between OXB and Plowshare to advance transformative therapies for patients living with debilitating conditions, leveraging more than three decades of OXB’s viral vector development and manufacturing expertise.

Plowshare’s program will be supported from OXB’s FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina.

Dr. Sébastien Ribault, Chief Business Officer of OXB, said, “By combining our deep expertise in viral vector development and GMP manufacturing with Plowshare’s innovative rare disease program, we look forward to supporting the advancement of potentially transformative therapies for patients with significant unmet medical needs.”

Kevin A. Strauss, MD, Founder and Chief Medical Officer of Plowshare Therapies, said, “Plowshare was created alongside the community it serves to get the best therapeutic science to patients who need it most. For any child with a rare disease, we demand manufacturing of the highest rigour. In OXB, we found a partner whose standards match our own.”